Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

PMDA announces darolutamide and trastuzumab package-insert revisions

添付文書改訂相談に基づく添付文書改訂(医薬品)を掲載しました

Published: 2026-11-16 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-11-17

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

On 2026-11-16, the Pharmaceuticals and Medical Devices Agency (PMDA) published consultation-based package-insert revisions for Bayer's Nubeqa tablets 300 mg (darolutamide) and Pfizer's trastuzumab BS intravenous infusion products 60 mg and 150 mg. For darolutamide, Section 7 adds a reference to the electronic package insert for lutetium vipivotide tetraxetan (177Lu) for dosing when used together in PSMA-positive metastatic castration-sensitive prostate cancer. For Pfizer's trastuzumab products, Section 5 adds a reference to tucatinib's electronic package insert for combination dosing in HER2-positive biliary tract cancer that has progressed after cancer chemotherapy and cannot be curatively resected, limited to cases where standard treatment is difficult. PMDA states that clinical trial results supported the clinical usefulness of these combinations and the appropriateness of the revisions; the trastuzumab comparison also records a terminology change for angioedema under serious adverse reactions.

Business Impact

Bayer and Pfizer, and healthcare professionals using the named products, may need to account for the added cross-references when reviewing combination-treatment dosing information. The trastuzumab revision concerns the specifically described biliary tract cancer setting, rather than an unrestricted change for all cancer uses.

Recommended Action

A product-information review could check darolutamide Section 7 and trastuzumab Section 5 against the referenced electronic package inserts, including the specified cancer settings and treatment limitations. The trastuzumab Section 11.1 terminology change could also be checked in the revised safety text.